(Q43041718)

12 November 2017

title

Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon (English)

1 reference

12 November 2017

1 reference

1 reference

José-Ignacio Riezu-Boj

3

1 reference

12 November 2017

4

1 reference

12 November 2017

Camps J

1

1 reference

12 November 2017

García-Granero M

2

1 reference

12 November 2017

de Alava E

5

1 reference

12 November 2017

Civeira MP

6

1 reference

12 November 2017

Castilla A

7

1 reference

12 November 2017

Prieto J

8

1 reference

12 November 2017

publication date

1 July 1994

1 reference

12 November 2017

number of pages

8

1 reference

inferred from page(s)

published in

Journal of Hepatology

1 reference

12 November 2017

volume

21

1 reference

12 November 2017

issue

1

1 reference

12 November 2017

page(s)

4-11

1 reference

Interferon for non-A, non-B chronic hepatitis

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Long-term follow-up of patients with chronic hepatitis C treated with α-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Histological outcome of chronic hepatitis C treated with a 12-month course of lymphoblastoid alfa interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Detection of hepatitis C viral sequences in blood donations by "nested" polymerase chain reaction and prediction of infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Avoiding false positives with PCR

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Replication of hepatitis C virus in peripheral blood mononuclear cells. Effect of alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Studies on the composition of the mononuclear cell infiltrates in liver from patients with chronic active delta hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Serum type III procollagen peptide concentrations in severe chronic active hepatitis: relationship to cirrhosis and disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

High Rate of Infectivity and Liver Disease in Blood Donors with Antibodies to Hepatitis C Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Persistent hepatitis C viraemia without liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2894%2980129-0

7 January 2021

10.1016/S0168-8278(94)80129-0

Identifiers

DOI

1 reference

12 November 2017

1 reference